{"id":1630,"date":"2023-05-17T07:00:00","date_gmt":"2023-05-17T05:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\/"},"modified":"2023-05-23T14:11:14","modified_gmt":"2023-05-23T14:11:14","slug":"ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\/","title":{"rendered":"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es sur Bylvay\u00ae (od\u00e9vixibat) lors du congr\u00e8s annuel ESPGHAN, attestant de son engagement \u00e0 faire progresser le traitement des maladies cholestatiques rares"},"content":{"rendered":"<p align=\"justify\"><strong>PARIS, FRANCE, le 17 mai 2023<\/strong> \u2013 Ipsen (Euronext\u00a0: IPN\u00a0: ADR\u00a0: IPSEY) annonce aujourd&#8217;hui que de nouvelles donn\u00e9es issues de son portefeuille croissant dans les maladies rares seront pr\u00e9sent\u00e9es lors du 55<sup>e<\/sup> congr\u00e8s annuel de la <em>European<\/em><em> Society for <\/em><em>Paediatric<\/em> <em>Gastroenterology<\/em><em>, <\/em><em>Hepatology<\/em><em> and Nutritions<\/em> (ESPGHAN), qui se tiendra \u00e0 Vienne, en Autriche du 17 au 20 mai 2023. Les six pr\u00e9sentations de donn\u00e9es, comprenant quatre pr\u00e9sentations orales, un poster et un e-poster, d\u00e9montrent de mani\u00e8re coh\u00e9rente l&#8217;efficacit\u00e9 et la tol\u00e9rabilit\u00e9 du m\u00e9dicament Bylvay\u00ae (od\u00e9vixibat) comme traitement potentiel des patients atteints du syndrome d&#8217;Alagille (SAG), une maladie cholestatique, et comme traitement des patients atteints de cholestase intrah\u00e9patique familiale progressive (PFIC).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>PARIS, FRANCE, le 17 mai 2023 \u2013 Ipsen (Euronext\u00a0: IPN\u00a0: ADR\u00a0: IPSEY) annonce aujourd&#8217;hui que de nouvelles donn\u00e9es issues de son portefeuille croissant dans les maladies rares seront pr\u00e9sent\u00e9es lors du 55e congr\u00e8s annuel de la European Society for Paediatric Gastroenterology, Hepatology and Nutritions (ESPGHAN), qui se tiendra \u00e0 Vienne, en Autriche du 17 au<\/p>\n","protected":false},"author":1,"template":"","categories":[],"tags":[],"class_list":["post-1630","press_release","type-press_release","status-publish","hentry","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ipsen pr\u00e9sentera de nouvelles donn\u00e9es sur Bylvay\u00ae (od\u00e9vixibat) lors du congr\u00e8s annuel ESPGHAN, attestant de son engagement \u00e0 faire progresser le traitement des maladies cholestatiques rares - Annual Report<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es sur Bylvay\u00ae (od\u00e9vixibat) lors du congr\u00e8s annuel ESPGHAN, attestant de son engagement \u00e0 faire progresser le traitement des maladies cholestatiques rares - Annual Report\" \/>\n<meta property=\"og:description\" content=\"PARIS, FRANCE, le 17 mai 2023 \u2013 Ipsen (Euronext\u00a0: IPN\u00a0: ADR\u00a0: IPSEY) annonce aujourd&#8217;hui que de nouvelles donn\u00e9es issues de son portefeuille croissant dans les maladies rares seront pr\u00e9sent\u00e9es lors du 55e congr\u00e8s annuel de la European Society for Paediatric Gastroenterology, Hepatology and Nutritions (ESPGHAN), qui se tiendra \u00e0 Vienne, en Autriche du 17 au\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\/\" \/>\n<meta property=\"og:site_name\" content=\"Annual Report\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-23T14:11:14+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/annualreport\\\/fr\\\/press-releases\\\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\\\/\",\"url\":\"https:\\\/\\\/www.ipsen.com\\\/annualreport\\\/fr\\\/press-releases\\\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\\\/\",\"name\":\"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es sur Bylvay\u00ae (od\u00e9vixibat) lors du congr\u00e8s annuel ESPGHAN, attestant de son engagement \u00e0 faire progresser le traitement des maladies cholestatiques rares - Annual Report\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/annualreport\\\/#website\"},\"datePublished\":\"2023-05-17T05:00:00+00:00\",\"dateModified\":\"2023-05-23T14:11:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/annualreport\\\/fr\\\/press-releases\\\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ipsen.com\\\/annualreport\\\/fr\\\/press-releases\\\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/annualreport\\\/fr\\\/press-releases\\\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ipsen.com\\\/annualreport\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es sur Bylvay\u00ae (od\u00e9vixibat) lors du congr\u00e8s annuel ESPGHAN, attestant de son engagement \u00e0 faire progresser le traitement des maladies cholestatiques rares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/annualreport\\\/#website\",\"url\":\"https:\\\/\\\/www.ipsen.com\\\/annualreport\\\/\",\"name\":\"Annual Report\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/annualreport\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ipsen.com\\\/annualreport\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/annualreport\\\/#organization\",\"name\":\"Annual Report\",\"url\":\"https:\\\/\\\/www.ipsen.com\\\/annualreport\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/annualreport\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ipsen.com\\\/annualreport\\\/wp-content\\\/uploads\\\/sites\\\/3\\\/2023\\\/12\\\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\\\/\\\/www.ipsen.com\\\/annualreport\\\/wp-content\\\/uploads\\\/sites\\\/3\\\/2023\\\/12\\\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"Annual Report\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/annualreport\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es sur Bylvay\u00ae (od\u00e9vixibat) lors du congr\u00e8s annuel ESPGHAN, attestant de son engagement \u00e0 faire progresser le traitement des maladies cholestatiques rares - Annual Report","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es sur Bylvay\u00ae (od\u00e9vixibat) lors du congr\u00e8s annuel ESPGHAN, attestant de son engagement \u00e0 faire progresser le traitement des maladies cholestatiques rares - Annual Report","og_description":"PARIS, FRANCE, le 17 mai 2023 \u2013 Ipsen (Euronext\u00a0: IPN\u00a0: ADR\u00a0: IPSEY) annonce aujourd&#8217;hui que de nouvelles donn\u00e9es issues de son portefeuille croissant dans les maladies rares seront pr\u00e9sent\u00e9es lors du 55e congr\u00e8s annuel de la European Society for Paediatric Gastroenterology, Hepatology and Nutritions (ESPGHAN), qui se tiendra \u00e0 Vienne, en Autriche du 17 au","og_url":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\/","og_site_name":"Annual Report","article_modified_time":"2023-05-23T14:11:14+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\/","url":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\/","name":"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es sur Bylvay\u00ae (od\u00e9vixibat) lors du congr\u00e8s annuel ESPGHAN, attestant de son engagement \u00e0 faire progresser le traitement des maladies cholestatiques rares - Annual Report","isPartOf":{"@id":"https:\/\/www.ipsen.com\/annualreport\/#website"},"datePublished":"2023-05-17T05:00:00+00:00","dateModified":"2023-05-23T14:11:14+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/annualreport\/fr\/"},{"@type":"ListItem","position":2,"name":"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es sur Bylvay\u00ae (od\u00e9vixibat) lors du congr\u00e8s annuel ESPGHAN, attestant de son engagement \u00e0 faire progresser le traitement des maladies cholestatiques rares"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/annualreport\/#website","url":"https:\/\/www.ipsen.com\/annualreport\/","name":"Annual Report","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/annualreport\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/annualreport\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/annualreport\/#organization","name":"Annual Report","url":"https:\/\/www.ipsen.com\/annualreport\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/annualreport\/wp-content\/uploads\/sites\/3\/2023\/12\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/annualreport\/wp-content\/uploads\/sites\/3\/2023\/12\/Latest_Ipsen-logo_168x48.svg","caption":"Annual Report"},"image":{"@id":"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/"}}]}},"parsely":{"version":"1.1.0","canonical_url":"https:\/\/ipsen.com\/annualreport\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\/","smart_links":{"inbound":0,"outbound":0},"traffic_boost_suggestions_count":0,"meta":{"@context":"https:\/\/schema.org","@type":"NewsArticle","headline":"Ipsen pr\u00e9sentera de nouvelles donn\u00e9es sur Bylvay\u00ae (od\u00e9vixibat) lors du congr\u00e8s annuel ESPGHAN, attestant de son engagement \u00e0 faire progresser le traitement des maladies cholestatiques rares","url":"http:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\/","mainEntityOfPage":{"@type":"WebPage","@id":"http:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\/"},"thumbnailUrl":"","image":{"@type":"ImageObject","url":""},"articleSection":"Non classifi\u00e9(e)","author":[{"@type":"Person","name":"IPSEN"}],"creator":["IPSEN"],"publisher":{"@type":"Organization","name":"Annual Report","logo":""},"keywords":[],"dateCreated":"2023-05-17T05:00:00Z","datePublished":"2023-05-17T05:00:00Z","dateModified":"2023-05-23T14:11:14Z"},"rendered":"<script type=\"application\/ld+json\" class=\"wp-parsely-metadata\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@type\":\"NewsArticle\",\"headline\":\"Ipsen pr\\u00e9sentera de nouvelles donn\\u00e9es sur Bylvay\\u00ae (od\\u00e9vixibat) lors du congr\\u00e8s annuel ESPGHAN, attestant de son engagement \\u00e0 faire progresser le traitement des maladies cholestatiques rares\",\"url\":\"http:\\\/\\\/www.ipsen.com\\\/annualreport\\\/fr\\\/press-releases\\\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\\\/\",\"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"http:\\\/\\\/www.ipsen.com\\\/annualreport\\\/fr\\\/press-releases\\\/ipsen-presentera-de-nouvelles-donnees-sur-bylvay-odevixibat-lors-du-congres-annuel-espghan-attestant-de-son-engagement-a-faire-progresser-le-traitement-des-maladies-cholestatiques-rares\\\/\"},\"thumbnailUrl\":\"\",\"image\":{\"@type\":\"ImageObject\",\"url\":\"\"},\"articleSection\":\"Non classifi\\u00e9(e)\",\"author\":[{\"@type\":\"Person\",\"name\":\"IPSEN\"}],\"creator\":[\"IPSEN\"],\"publisher\":{\"@type\":\"Organization\",\"name\":\"Annual Report\",\"logo\":\"\"},\"keywords\":[],\"dateCreated\":\"2023-05-17T05:00:00Z\",\"datePublished\":\"2023-05-17T05:00:00Z\",\"dateModified\":\"2023-05-23T14:11:14Z\"}<\/script>","tracker_url":"https:\/\/cdn.parsely.com\/keys\/ipsen.com\/p.js"},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/press_release\/1630","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/press_release\/1630\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/media?parent=1630"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/categories?post=1630"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/tags?post=1630"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}